Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
4
50%
Ph phase_1
1
13%
Ph phase_2
3
38%

Phase Distribution

1

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
4(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 23 (37.5%)
Phase 34 (50.0%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00002878
completedphase_2

Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer

NCT00002826
completedphase_2

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00004217
completedphase_3

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00005823
completedphase_3

Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia

NCT00003190
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00002878Phase 3

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
NCT00002826Phase 2

Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer

Completed
NCT00004217Phase 2

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed
NCT00005823Phase 3

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed
NCT00003190Phase 3

Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed
NCT00006363Phase 3

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Completed
NCT00002912Phase 1

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

Completed
NCT00002937Phase 2

Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8